Results 11 to 20 of about 3,663 (172)

PCSK9 Inhibitors Reduce Oxidative Stress Biomarkers in Heterozygous Familial Hypercholesterolemia. [PDF]

J Cell Mol Med
ABSTRACT Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, such as alirocumab and evolocumab, effectively reduce LDL‐C levels, improve cardiovascular outcomes, and are well tolerated in the treatment of heterozygous familial hypercholesterolemia (HeFH).
Woźniak-Szczepocka A, Pawlos A, Gorzelak-Pabiś P, Broncel M, Bukowska B, Woźniak E.   +5 more
europepmc   +2 more sources

Alirocumab and Lipid Levels, Inflammatory Biomarkers, Metabolomics, and Safety in Patients Receiving Maintenance Dialysis: The ALIrocumab in DIALysis Study (A Phase 3 Trial to Evaluate the Efficacy and Safety of Biweekly Alirocumab in Patients on a Stable Dialysis Regimen)Plain-Language Summary

Kidney Medicine, 2022
Rationale & Objective: The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor alirocumab is used in the general population to treat dyslipidemia, but little is known about the effects of alirocumab on lipid levels, biomarkers, the ...
Cara East, Kyle Bass, Ankit Mehta, Gelareh Rahimighazikalayed, Sandy Zurawski, Teodoro Bottiglieri   +5 more
doaj   +1 more source

Effect of alirocumab on cataracts in patients with acute coronary syndromes

BMC Ophthalmology, 2023
Background Some data suggest that low levels of low-density lipoprotein cholesterol (LDL-C) are associated with risk of cataracts. Proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitors reduce LDL-C below levels achieved with statins alone.
Gaspard Suc, Gregory G. Schwartz, Shaun G. Goodman, J. Wouter Jukema, Garen Manvelian, Yann Poulouin, Robert Pordy, Michel Scemama, Michael Szarek, Ph. Gabriel Steg, ODYSSEY OUTCOMES Investigators   +10 more
doaj   +1 more source

Intensified lipid-lowering treatment with alirocumab in patients with coronary heart disease

Open Heart, 2021
Background Atherosclerotic cardiovascular disease is the leading cause of death and disability in the Western world.Objective To characterise adults with confirmed coronary heart disease (CHD) and primary heterozygous familial or non-familial ...
Peter Bramlage, Daniel Steffens, Julia Müller, Cornelia Dorn, W Dieter Paar, Celine Scheeff, Mario Kasner, U Rauch-Kröhnert   +7 more
doaj   +1 more source

Effect of proprotein convertase subtilisin/kexin type 9 inhibition on cancer events: A pooled, post hoc, competing risk analysis of alirocumab clinical trials

Cancer Medicine, 2023
Objective Assess the risk of new and worsening cancer events among participants who received the lipid‐lowering therapy alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor. Design Pooled post hoc analysis. Setting Six phase 3 or phase 4
Kusha A. Mohammadi, Taylor Brackin, Gregory G. Schwartz, Philippe Gabriel Steg, Michael Szarek, Garen Manvelian, Robert Pordy, Sergio Fazio, Gregory P. Geba   +8 more
doaj   +1 more source

Optimized Treatment of Refractory Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia With Alirocumab (OPTIMIZE)

Frontiers in Cardiovascular Medicine, 2022
BackgroundLow-density lipoprotein cholesterol (LDL-C) is a major risk factor for atherosclerotic cardiovascular disease (ASCVD). In confirmatory trials, proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab substantially lowered LDL-C and ...
Isabella Sudano, Francois Mach, Tiziano Moccetti, Thilo Burkard, Christian Fahe, Alain Delabays, Hans Rickli, Pierre-Frédéric Keller, Jörn Dopheide, Jörn Dopheide, Sereina Bodenmann, Tom Fiolka, Georg Ehret, David Spirk, David Spirk   +14 more
doaj   +1 more source

Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol

Cardiovascular Diabetology, 2020
Background Mixed dyslipidemia [elevated non-high-density lipoprotein cholesterol (non-HDL-C) and triglycerides (TGs), and decreased HDL-C] is common in type 2 diabetes mellitus (T2DM) and is associated with increased cardiovascular risk.
Helen M. Colhoun, Lawrence A. Leiter, Dirk Müller-Wieland, Bertrand Cariou, Kausik K. Ray, Francisco J. Tinahones, Catherine Domenger, Alexia Letierce, Marc Israel, Rita Samuel, Stefano Del Prato   +10 more
doaj   +1 more source

Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on the number needed to treat

Frontiers in Cardiovascular Medicine, 2022
AimsThe efficacy of anti-proprotein convertase subtilisin/Kexin type 9 (PCSK9) monoclonal antibodies in patients with atherosclerotic cardiovascular disease (ASCVD) remains unclear.
Hong-Fei Wang, Hong-Fei Wang, Yu-Cheng Mao, Yu-Cheng Mao, Xin-Yi Xu, Xin-Yi Xu, Si-Yu Zhao, Si-Yu Zhao, Dan-Dan Han, Dan-Dan Han, Shi-Yao Ge, Shi-Yao Ge, Kai Song, Kai Song, Chang Geng, Chang Geng, Qing-Bao Tian, Qing-Bao Tian   +17 more
doaj   +1 more source

Alirocumab effect on preventing periprocedural ischaemic events in coronary heart disease patients undergoing coronary stenting (APPEASE trial): study protocol of a multicentre, open-label, randomised controlled trial

BMJ Open, 2023
Introduction Percutaneous coronary intervention (PCI)-related myocardial infarction (type 4a MI) and major periprocedural myocardial injury have been demonstrated leading to poor prognosis of patients with coronary heart disease (CHD) undergoing elective
Yang Chen, Suhua Li, Lianxiong Yuan, Zhenyu Xiong, Jinlai Liu, Xiaoxian Qian, Longgen Xiong, Leile Tang, Zhuoshan Huang, Xiaodong Zhuang, Shaozhao Zhang, Yiquan Huang, Aiwen Lin, Odong Christopher, Bingyuan Wu, Yesheng Ling, Qiang Jie, Xinxue Liao   +17 more
doaj   +1 more source

Relationship Between Low‐Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid‐Lowering Strategies

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2016
BackgroundAlirocumab undergoes target‐mediated clearance via binding of proprotein convertase subtilisin/kexin type 9 (PCSK9). Statins increase PCSK9 levels; the effects of nonstatin lipid‐lowering therapies are unclear.
Jacques Rey, Franck Poitiers, Tobias Paehler, Aurélie Brunet, A. Thomas DiCioccio, Christopher P. Cannon, Howard K. Surks, Jean‐Louis Pinquier, Corinne Hanotin, William J. Sasiela   +9 more
doaj   +1 more source